Thrombomodulin is a Strong Predictor of Multiorgan Dysfunction Syndrome in Patients With Sepsis

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 5, 2015, Pages 469-474

  Mihajlovic, Dunja M ^a   Lendak, Dajana F ^b   Draskovic, Biljana G ^b   Mikic, Aleksandra S Novakov ^b   Mitic, Gorana P ^b   Cebovic, Tatjana N ^b   Brkic, Snezana V ^b  

^a Emergency Centre   (Serbia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

endothelial dysfunction; hemostasis; hypercoagulability

Indexed keywords

ANTITHROMBIN; PROTEIN C; PROTEIN S; THROMBOMODULIN;

ADULT; APACHE; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; BLOOD; HEMOSTASIS; MIDDLE AGED; THROMBOPHILIA;

FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEPSIS; THROMBOMODULIN; THROMBOPHILIA;

EID: 84933033931     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613508600     Document Type: Article

References (32)

1. Dombrovskiy V, Martin A, Sunderram J, Paz H. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007 ; 35 (5). 1414-1415
2. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 ; 302 (21). 2323-2329
3. Levi M, de Jonge E, van Der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003 ; 16 (1-2). 43-47
4. Mihajlovic D, Draskovic B, Brkic S, Mitic G, Lendak D. Endothelial dysfunction and interaction between inflammation and coagulation in sepsis and systemic inflammatory response syndrome (SIRS). Health Med. 2012 ; 6 (4). 1309-1314
5. Levi M, Van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005 ; 15 (7). 254-259
6. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005 ; 131 (4). 417-430
7. Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med. 2001 ; 29 (7 suppl). S62 - S68
8. Califano F, Giovanniello T, Pantone P, et al. Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci. 2000 ; 4 (3). 59-66
9. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood. 1990 ; 76 (10). 2024-2029
10. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010 ; 14 (1). R15
11. OkamotoTTanigamiHSuzukiKShimaokaM. Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract.2012;20120:614545. http://www.hindawi.com/journals/ccrp/2012/614545/abs/. Accessed June 30, 2013.
12. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med. 2012 ; 40 (9). 2704-2708
13. Levi M, van der Poll T. Coagulation in sepsis: all bugs bite equally. Crit Care. 2004 ; 8 (2). 99-100
14. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis - a systematic review. Crit Care. 2012 ; 16 (1). R7
15. Dellinger R, Levy M, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 ; 39 (2). 165-228
16. Bone R, Balk R, Cerra F, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest. 1992 ; 101 (6). 1644-1655
17. Levy M, Fink M, Marshall J, et al. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2001 2003 ; 31 (4). 1250-1256
18. Gaieski D, Mikkelsen M, Band R, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010 ; 38 (4). 1045-1053
19. Zubert S, Funk D, Kumar A. Antibiotics in sepsis and septic shock: like everything else in life, timing is everything. Crit Care Med. 2010 ; 38 (4). 1211-1212
20. Rivers E, McIntyre L, Morro D, Rivers K. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ. 2005 ; 173 (9). 1054-1065
21. Ely EW, Laterre PF, Angus DC, et al. PROW-ESS Investigators: drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003 ; 31 (1). 12-19
22. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006 ; 17 (7). 521-526
23. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers. 2011 ; 16 (S1). S11 - S21
24. Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost. 2005 ; 3 (5). 976-982
25. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011 ; 9 (suppl 1). 168-173
26. Jones A, Trzeciak S, Kline J. The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009 ; 37 (5). 1649-1654
27. Koh CY, Kim YS, Shin TY, Ha YR. Comparing the usefulness of the initial acute physiologic and chronic health evaluation (APACHE) II score in the emergency department (ED) and the mortality in emergency department sepsis (MEDS) score for predicting the prognosis of septic patients admitt. Korean J Criti Care Med. 2008 ; 23.2: 90-95
28. Lin SM, Wang YM, Lin HC, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008 ; 36 (3). 683-689
29. Dharmasaroja P, Dharmasaroja PA, Sobhon P. Increased plasma thrombomodulin levels in cardioembolic stroke. Clin Appl Thromb Hemost. 2012 ; 18 (3). 289-293
30. Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost. 2001 ; 7 (1). 5-9
31. Dhainaut JF, Yan SB, Cariou A, Mira JP. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med. 2002 ; 30 (5). S318 - S324
32. Kato T, Sakai T, Kato M, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J. 2013 ; 11 (1). 3